top of page
Wireframe - 8.png

Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases

Cyrus Babak Ravandi, William R. Mowrey, Ayan Chatterjee, Fariba Khanshan, Parham Haddadi, Juan Carlos Mobarec, Simon Lambden, Tina Eliassi-Rad, Piero Ricchiuto, Gabriel Risa

Working Paper

|

June 20, 2026

Evaluating the potential applications of a medicine is a fundamental challenge in drug development. There is a lack of standardized, decision-oriented benchmarks that test whether computational models can generalize therapeutic hypotheses across diseases in ways that reflect real-world pharmaceutical investment decision making. To address this gap, we introduce two complementary resources: the Indication Expansion Investment Decision Network (IxIDN) and the Orphanet Rare Disease Ontology Negative-network (ORDON). IxIDN is a clinical-trial-derived positive benchmark constructed by projecting drug–disease associations from pharmaceutical clinical trials into a disease–disease network; each edge connects disease pairs that have entered clinical trials for the same drug, thereby capturing cases when concrete indication-expansion decisions have been made. The current release contains 574 rare diseases and 5,336 edges. In contrast, ORDON serves as a stringent, biology-aware negative benchmark derived from the authoritative Orphanet Rare Disease Ontology. It identifies maximally distant disease pairs according to curated hierarchical structure and genetics-linked inheritance patterns, providing 793 rare diseases and 5,000 edges that represent high-separation negative candidates across therapeutic areas. Together, IxIDN and ORDON enable rigorous cross-evidence generalization from clinical trials to disease ontology, testing for Disease– Disease Association Learning (DDAL), a core task for mechanism-centered drug repurposing and indication expansion. All data are publicly available with detailed metadata, enabling reproducible evaluation of models on transparent, decision-relevant benchmarks.

citation

Ravandi, C. B., Mowrey, W. R., Chatterjee, A., Khanshan, F., Haddadi, P., Mobarec, J. C., Lambden, S., Eliassi-Rad, T., Ricchiuto, P., & Risa, G. (2026). Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases [Preprint]. bioRxiv. https://doi.org/10.64898/2026.06.15.732135

topics

Research Methods & Data

Health & Wellbeing

Artificial Intelligence

Artificial Intelligence

related work

Rectangle 35

Measuring Agency-Amplifying AI Literacy: The HuskyAI Coaching Platform for Workforce Readiness

July 2026

HuskyAI is a web platform on which students develop AI knowledge by working through authentic

Artificial Intelligence

Artificial Intelligence

Working Paper

Rectangle 35

Measuring Agency-Amplifying AI Literacy: The HuskyAI Coaching Platform for Workforce Readiness

July 2026

HuskyAI is a web platform on which students develop AI knowledge by working through authentic

Artificial Intelligence

Artificial Intelligence

Working Paper

Rectangle 35

Measuring Agency-Amplifying AI Literacy: The HuskyAI Coaching Platform for Workforce Readiness

July 2026

HuskyAI is a web platform on which students develop AI knowledge by working through authentic

Artificial Intelligence

Artificial Intelligence

Working Paper

bottom of page